Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors
On May 17, 2022, the Board of Directors (the “Board”) of Mereo BioPharma Group plc (the “Company”) appointed Dr. Abdul Mullick to
the Board, effective immediately. Following Dr. Mullick’s appointment the Board will consist of ten members. Following the Company’s Annual General Meeting, Dr. Peter Fellner stepped down as chair of the Board and is being
replaced by Michael Wyzga, who will serve as chair of the Board going forward.
Dr. Mullick currently serves as President & Chief Executive
Officer of Kyowa Kirin International plc (“KKI”), a subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151) the Japan-based global specialty pharmaceutical company. During his four years at KKI, Dr. Mullick successfully led the launch of two
new rare disease products across Europe, the Gulf Cooperation Council Markets (GCC) and other growth markets, including for the treatment of X-linked hypophosphatemia, a disease characterized by low levels of
phosphate in the blood. He also led a drive to enhance patient and customer care, resulting in improved profitability, as well as accelerating the digital transformation across the entire value chain. Prior to KKI, Dr. Mullick held senior
positions at Vifor Pharma as Head of Global Strategic Marketing, Novartis as Global Head of the Diabetes Franchise and at Sanofi where he held roles at the country, regional and global levels. Most notably, he spent over eight years at Genzyme
leading rare and ultra-rare disease businesses in Europe, Asia (including China and Japan) and the United States, as well as heading the rare disease global strategy and marketing function. Dr. Mullick graduated with a PhD in Molecular Biology
from Bristol University in the UK.
Michael Wyzga has served on our Board since April 2019. Mr. Wyzga is currently the President of MSW Consulting
Inc., a strategic consulting group focused in the life sciences area. From December 2011 until November 2013, Mr. Wyzga served as President and Chief Executive Officer and a member of the board of directors of Radius Health, Inc. Prior to that,
Mr. Wyzga served in various senior management positions at Genzyme Corporation, including as Chief Financial Officer from July 1999 until November 2011. Mr. Wyzga is a member of the boards of directors of Adagio Therapeutics, Inc. and
LogicBio and is Chairman of the board of directors of GenSight Biologics S.A. and of X4 Biologics. Mr. Wyzga previously served as a member of the boards of directors of Exact Sciences Corporation, Idenix Pharmaceuticals, Inc. and Altus
Pharmaceuticals, Inc., and as a member of the supervisory board of Prosensa Holding B.V. He received an M.B.A. from Providence College and a B.S. from Suffolk University.
There are no arrangements or understandings between Dr. Mullick, Mr. Wyzga and any other persons in connection with the appointments described
above. Dr. Mullick and Mr. Wyzga do not have any family relationships with any executive officer or director of the Company, and none of them is a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Each of Dr. Mullick and Mr. Wyzga will receive compensation as
non-employee directors in accordance with the non-employee director compensation practices described in the Company’s filings with the Securities and Exchange
Commission.
On May 17, 2022, the Company issued a press release announcing Dr. Mullick’s appointment, a copy of which is furnished as
Exhibit 99.1 hereto and incorporated by reference herein.